Category:Cancer treatments
From WikiMD's WELLNESSPEDIA
Subcategories
This category has the following 8 subcategories, out of 8 total.
Pages in category "Cancer treatments"
The following 200 pages are in this category, out of 348 total.
(previous page) (next page)A
- Abituzumab
- ABT-510
- Active immunotherapy
- Active surveillance
- ADE (chemotherapy)
- Adecatumumab
- Adegramotide
- Adjuvant therapy
- Adoptive cell transfer
- Advaxis
- AFP-07
- ALK inhibitor
- Alpelisib
- Alternative cancer treatments
- Amatuximab
- AMG 319
- Amphinex
- Angiostatin
- Annamycin
- Anti-VEGF
- Antibody–drug conjugate
- Antihormone therapy
- Template:Antineoplastic-agents-stub
- Asparaginase erwinia chrysanthemi
- ATC code L01
- Atrasentan
- Auger therapy
- Autologous tumor cell
- Avapritinib
- Avicine
- Axicabtagene ciloleucel
B
C
- Camidanlumab tesirine
- Cancer drugs
- Cancer Treatment
- Cantuzumab mertansine
- Cantuzumab ravtansine
- Capmatinib
- Capsaicin
- CAR T cell
- CAR-302,196
- Carmustine
- Carotuximab
- Cellular adoptive immunotherapy
- Chemoimmunotherapy
- Chemosensitizer
- Chemotherapy
- Cirmtuzumab
- Cisplatin
- Citatuzumab bogatox
- Cixutumumab
- Clevegen
- Clostridium novyi-NT
- Cofetuzumab pelidotin
- Coley's toxins
- Conatumumab
- Continuous hyperthermic peritoneal perfusion
- Cryoimmunotherapy
- Cytarabine
- Cytopenia
D
E
F
G
H
I
- Icrucumab
- Idecabtagene vicleucel
- Image-guided radiation therapy
- Imexon
- IMM-101
- Immunotoxin
- Infigratinib
- Insulin potentiation therapy
- Intetumumab
- Intraoperative electron radiation therapy
- Intraoperative radiation therapy
- Iratumumab
- IRGD peptides
- Irreversible electroporation
- Isolated organ perfusion technique
L
- Labetuzumab
- Leronlimab
- Lexatumumab
- Liarozole
- Limb perfusion
- Linifanib
- Lintuzumab
- Liposomal daunorubicin
- Lirentelimab
- Lirilumab
- Lisocabtagene maraleucel
- List of chemotherapeutic agents
- List of drugs: Y
- List of hormonal cytostatic antineoplastic agents
- Lomustine
- Loncastuximab tesirine
- Lorlatinib
- Lorvotuzumab mertansine
- Low-dose chemotherapy
- Lucatumumab
- Lucitanib
- Lumretuzumab
- Lymphokine-activated killer cell
M
- Magnetic-targeted carrier
- Maintenance therapy
- Mapatumumab
- Marimastat
- Masitinib
- Maslimomab
- MDX-1097
- Melphalan flufenamide
- Metastasectomy
- Metronomic therapy
- Microwave ablation
- Mifamurtide
- Milatuzumab
- Minretumomab
- Mitomycin C
- Mitomycin Pyelocalyceal
- Mitotic inhibitor
- Mitumomab
- Mocetinostat
- Moist desquamation
- Monalizumab
- Monoclonal antibody
- Monoclonal antibody therapy
- MOPP
